Healx has previously secured investigational new drug (IND) approval from the U.S. FDA for fragile X syndrome and is in the early AI-discovery or preclinical stages for a number of other conditions spanning oncology, renal, and neurology.
Organizations Involved
Children’s Tumor Foundation
Founders
Tim Guilliams, David Brown
Company Description
Healx is a rare disease biotechnology company that uses generative AI for drug discovery.
Market
Rare Diseases
Location
Cambridge,
UK
Coinvestors
Atomico, R42, Ayana Capital, Balderton, Btov, Global Brain, Jonathan Milner, O2h, VU Venture Partners